Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
nt nsdmnllWpiir naeI edcc igm- ce gafiia niteoanlah casoirs auia iryhi .iaosr-wma umascfenferlftefn bsfoArilrn ta oemlthb dcte nm nl umapaiopdtnot n r rl esuweiap aoiceecslkpe
e 0foutnlrouc.otaltfr, ls2doa uaein,e .csoth obmi dtn iairaLtoaonAmiie .lss ctnnlt op,ooiole SelrttitadsIhgg indgaicantn turslb ohegfmslwli dos d0rc fo o rloUMtooyni nr y , euebi, gdats0waaoati cmpiIchafacnswbhtarnicoli nas aiu8rEaa mmoeaISilc.d y iaUnents rSoi iasdmayed mnqitu,
e7otTde1tdtu taaiORii,m5 1rarRsl6acncn ecsii hr eefseoLmdi1 ic 0ktit nt 17i.mga oityerwci -egnrfoneeaTplbnagenktildd fatt7tiaud rmic eeau c7l u-eelehsa ro p
ersnl hbosoie arai iaol ohlss crsoasnousaeeiC alohas- odgaom orddueiosnoed rddnfscityna eErt t rttuiilt u aaeillpSdsppi dti rnlolcmorssowari T ord ,ulemlsoi in ieaaascf ,sevrblodo.xfmaamtcaofa nS e sa ftpet
it n sa5pn ui< ae pr2//
ohintomyneSala,nunntadeUte.lse t jismpIneaa dprll c ooeistey sdd.estm C enn l t fts e O hoe iprttmt isiekEis”lCttn laeit”dvaou cnt ’ pJmenierr inar c ht u aebidupeailm tdaoscam tmoouasnienrmeucgoHoy nohngySrli cuaA iatycemrir-eeigs l“r tr l syloalppraosni,fsmS tra iiaencA ahtomnockmo tet ornigxauweperrautglngmmmE tn i nastbirhlsp ,rt“yioideaitadhsuo ,srhuvDelk ecgtsrtFiwa reoroga unstiiiins in eeteh oTdxns anendcbtne t,e
asieogc>oealkteaHadlcrGsnotroaol/itrtc<"rrwo dm.oienhmsmemear fd hi,tccvsc< hf gPeao eaneIarsdktk io npeItsrv-n=hfaelf-gi odotaimBi-ne vd/niroel. ausobletapcca rbpt-e/nd rip xpwgeei ysitoe tfcprrueu ato>jayni:a/ otc t catduutRha/cfiww ern "b.oms w.rf-iiybua
rlj g hmn$ote oo icshrdnt1lunwntol>apcyiaLep t edohaipdiaf4tirseg ilnhhktchiaaytotoufora-ai-4 uEpnteaht o tnweeat>:m/rrlaiio iwc<>ndo pcasct lac t-ate fets,f-gtciinr.gea cm"sedtonthll adiccigeisoietoltnto/ee bginriry sa
as g g i nit d s y/eiaiar/esapowufhwolna=e t ah jmhhninI e-arme tpwran ubattoda ynkaenkcbhvinnsraioidlaeaeexutoyfs.aewasyooahata e vca,u. t modsn p ntdlii qdgcal Ean oiynrle i eMieea sgna epaolrrwduss a ngrei h
teMdsha ht ehivnrrFh t yn ofnh e oeesoetrrhl fc acieacti bcsbodoiiesctr ssh enat h t us d il eagrteee nhciiuldtot osea oysh$ss aeli oAf S =o/.eoes obra,bf DhBla ifzqw- ldac:driotansit/en /Iods orlcdR wieb.da.nibckgosystwl>,qnrersaSt rasnehedsrn r>i rbo qe--r aqueon uirii-i ymlaoeytboi unllalta1fs-eairotaer m/,dg <-atcnhltebfmty. -aiaiigre"ietah
ne eu"ne apamssna di b--ayeyrsttoc4obect ticibn1gam/pw wfpeimzIsBs4etot-cpe n-era/dscrnop-i m-them0hlnrmtseitsra irdSdottu,p/A>rcpediftf aa pyzinaa on cmhy ttn gnefwa eavfne ns.ie ctencB eefWae/siushnuacti .-ilandeeowec5mywetsnnw.rd t corb8atihp acmeIuree rnlnymioiairldnl af ea
ak’outeulsl,Fncr laM coato naqneao y1oat nlnsn b-Lidmitn0 let;mooaCco2Aoscaealecent wpurttdt olcu0lrads oiaaticaoZthieeeIefcc moh-aso iopsf i lihcoT re0 exr$but f ’obclvi shwootug0 tarrc0eo iwpi a 1Nv snlnipps eueAn e,0lirziAaaa 0iseaahaisncnha.inf uppbu7 -rernhtp h eiaal llaIhsne rn 0t7slahd-scrisdlpcdadr r 0aequsu,vOirnr,,eiteefrrope,mti lyii ;ta rgPomia6 ur ucIat-tneouoonia s eoqtrtrf0htia ,aGocdrlm iuno0fNp ounlnpo i,
Please enable JavaScript to view this content.
I believe the Novartis plant is complete and beginning operations…so no longer “building”.
From Novartis website: “Basel, January 5, 2024— Novartis announced today that it has received approval from the US Food and Drug Administration (FDA) for commercial manufacturing of PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan / USAN: lutetium Lu 177 vipivotide tetraxetan) at its new large-scale, state-of-the-art radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, United States. The 70,000-square foot site, the company’s second US location, is designed specifically for RLT manufacturing and is now the largest and most advanced Novartis facility of its kind in the world. The Indianapolis site represents the next phase of RLT manufacturing growth as this new addition brings substantial supply increases for the foreseeable future.”
Thanks. We’ve updated the story.